Form 4: Apogee CMO Sells Shares Under Pre-Planned 10b5-1 Plan

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, sold 2,725 shares of common stock in pre-planned transactions.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), reported the sale of common stock.
• The transactions occurred on September 3, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
• A total of 2,535 shares were sold at a weighted average price of $37.82 per share, with prices ranging from $37.39 to $38.37.
• An additional 190 shares were sold at a weighted average price of $38.55 per share, with prices ranging from $38.54 to $38.55.
• Following these transactions, Mr. Dambkowski beneficially owns 233,548 shares of Apogee Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the execution under a pre-planned Rule 10b5-1 plan mitigates any negative interpretation, suggesting a scheduled personal financial event rather than a reaction to company-specific news.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than a reaction to recent material non-public information.

Negatives

• The transactions represent a reduction in direct beneficial ownership by a key executive, which can sometimes be perceived negatively by investors, although mitigated by the 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to Apogee Therapeutics and does not provide broader industry context or trends. Insider sales under 10b5-1 plans are common across various industries for personal financial planning.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the pre-planned nature of the sale under Rule 10b5-1 suggests it is not based on new material information, thus limiting significant impact.

Key Dates

Recommendation

The filing reports a pre-planned insider sale under a Rule 10b5-1 plan, which typically indicates a scheduled diversification or liquidity event rather than a reaction to new material information. While it reduces insider ownership, it does not inherently signal a change in the company's fundamental outlook, thus a 'hold' recommendation is appropriate based solely on this transactional report.

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Carl Dambkowski, Stock Sale, 10b5-1 Plan, Chief Medical Officer